BioCentury
ARTICLE | Company News

FDA reviewing Mitsubishi's edaravone for ALS

August 30, 2016 7:00 AM UTC

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) said FDA accepted an NDA for edaravone ( MCI-186) to treat amyotrophic lateral sclerosis (ALS). Its PDUFA date is June 16, 2017. ...